Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFORD: mFOLFOXIRI vs mFOLFOX6 in Postoperative MRD Positive Stage II-III Colorectal Cancer
NCT05427669Phase 3Not yet recruiting
- Sponsor
- Yanhong Deng
- Start
- Oct 2022
- Primary completion
- Jul 2025
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC), sponsored by Yanhong Deng. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05427669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05427669.